Gahan J Pandina

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi request reprint Risperidone and cognitive function in children with disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Biol Psychiatry 62:226-34. 2007
  2. ncbi request reprint Risperidone in the management of disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 16:379-92. 2006
  3. ncbi request reprint Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, NJ 08560, USA
    J Autism Dev Disord 37:367-73. 2007
  4. doi request reprint Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Affect Disord 118:139-46. 2009
  5. doi request reprint Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:51-9. 2010
  6. ncbi request reprint Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 41:68-90. 2008
  7. ncbi request reprint Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 40:41-57. 2007
  8. doi request reprint Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08560, USA
    J Child Adolesc Psychopharmacol 19:749-56. 2009
  9. doi request reprint Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
    J Child Adolesc Psychopharmacol 18:337-45. 2008
  10. ncbi request reprint Direct health care costs for children with pervasive developmental disorders: 1996-2002
    Scott C Flanders
    Regional Outcomes Research, Ortho McNeil Janssen Scientific Affairs, LLC, 740 Waterford Drive, Grayslake, IL 60030, USA
    Adm Policy Ment Health 34:213-20. 2007

Detail Information

Publications19

  1. ncbi request reprint Risperidone and cognitive function in children with disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Biol Psychiatry 62:226-34. 2007
    ..Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed...
  2. ncbi request reprint Risperidone in the management of disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 16:379-92. 2006
    ..As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters...
  3. ncbi request reprint Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, NJ 08560, USA
    J Autism Dev Disord 37:367-73. 2007
    ..7.2 (1.4), P<0.05; ES=-0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism...
  4. doi request reprint Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Affect Disord 118:139-46. 2009
    ....
  5. doi request reprint Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:51-9. 2010
    ..In conclusion, PaRTS-D may be useful in symptom presence and severity assessments from the patient's perspective and as an adjunctive to other instruments in major depressive disorder diagnosis and response to treatment...
  6. ncbi request reprint Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 41:68-90. 2008
    ..The Patient-Rated Troubling Symptoms Scale for Anxiety (PaRTS-A) instrument was developed to provide an individualized assessment of patient relevant GAD symptoms...
  7. ncbi request reprint Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 40:41-57. 2007
    ....
  8. doi request reprint Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08560, USA
    J Child Adolesc Psychopharmacol 19:749-56. 2009
    ..The aim of this study was to evaluate cognitive effects from long-term risperidone treatment for disruptive behavior disorders (DBDs) in children and adolescents...
  9. doi request reprint Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
    J Child Adolesc Psychopharmacol 18:337-45. 2008
    ..The aim of this study was to determine the long-term safety of risperidone as maintenance therapy in children and adolescents with disruptive behavior disorders (DBDs) and normal intelligence...
  10. ncbi request reprint Direct health care costs for children with pervasive developmental disorders: 1996-2002
    Scott C Flanders
    Regional Outcomes Research, Ortho McNeil Janssen Scientific Affairs, LLC, 740 Waterford Drive, Grayslake, IL 60030, USA
    Adm Policy Ment Health 34:213-20. 2007
    ..1,469 vs. $2,404, respectively, P < 0.0001). Children with PDD incur significantly greater health care costs when compared with children with other chronic pediatric diseases...
  11. ncbi request reprint Risperidone for treatment-refractory major depressive disorder: a randomized trial
    Ramy A Mahmoud
    Ortho McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA
    Ann Intern Med 147:593-602. 2007
    ..Major depressive disorder has high prevalence, morbidity, and mortality. Inadequate results with antidepressants have prompts addition of a nonstandard treatment (augmentation therapy)...
  12. doi request reprint A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08560, USA
    J Clin Psychopharmacol 30:235-44. 2010
    ..6% vs 0.0%), and myalgia (1.0% vs 0.0%). The paliperidone palmitate treatment was efficacious and generally tolerated across the dose range (25, 100, or 150 mg eq.) in adult patients with acutely exacerbated schizophrenia...
  13. ncbi request reprint Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003
    Scott C Flanders
    Ortho McNeil Janssen Scientific Affairs, L L C, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 17:312-27. 2007
    ..The aim of this study was to compare clinical and health services outcomes in pediatric inpatients prescribed an atypical antipsychotic (AA) to those not prescribed an AA at discharge...
  14. doi request reprint Cognitive effects of topiramate in migraine patients aged 12 through 17 years
    Gahan J Pandina
    Psychiatry, Johnson and Johnson Pharmaceutical Research and Development L L C, Titusville, New Jersey 08560, USA
    Pediatr Neurol 42:187-95. 2010
    ..Learning, memory, and executive function were unchanged. The tolerability profile, including cognitive adverse events, appeared to be acceptable...
  15. pmc Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study
    Rohan Ganguli
    Western Psychiatric Institute and Clinic, O Hara Street, Pittsburgh, PA 15213 2593, USA
    BMC Med 6:17. 2008
    ..This paper assesses the short-term results of strategies for the discontinuation of olanzapine when initiating risperidone...
  16. ncbi request reprint Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia
    Gahan J Pandina
    Hum Psychopharmacol 22:326-7; author reply 328. 2007
  17. ncbi request reprint A discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia
    Georges M Gharabawi
    J Clin Psychiatry 68:333; author reply 334. 2007
  18. ncbi request reprint Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials
    Peter S Jensen
    Center for the Advancement of Children s Mental Health, Columbia University, New York State Psychiatric Institute, New York, NY, USA
    Eur Child Adolesc Psychiatry 16:104-20. 2007
    ..While there have been studies with duration up to 2 years, no definitive data are available that suggest long-term safety; additional studies are warranted...
  19. ncbi request reprint No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series
    Joseph Gonzalez-Heydrich
    Children s Hospital Boston, Fegan 8, 300 Longwood Avenue, Boston, MA 02115, USA
    J Child Adolesc Psychopharmacol 14:295-310. 2004
    ..The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders...